Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $945000.0.

  • Summit Therapeutics' Change in Accured Expenses fell 8396.67% to $945000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 3528.19%. This contributed to the annual value of $11.9 million for FY2024, which is 59974.76% up from last year.
  • As of Q3 2025, Summit Therapeutics' Change in Accured Expenses stood at $945000.0, which was down 8396.67% from $14.0 million recorded in Q2 2025.
  • Summit Therapeutics' Change in Accured Expenses' 5-year high stood at $14.0 million during Q2 2025, with a 5-year trough of -$7.6 million in Q1 2025.
  • Over the past 5 years, Summit Therapeutics' median Change in Accured Expenses value was $945000.0 (recorded in 2025), while the average stood at $1.4 million.
  • Examining YoY changes over the last 5 years, Summit Therapeutics' Change in Accured Expenses showed a top increase of 1538857.14% in 2023 and a maximum decrease of 107945.21% in 2023.
  • Summit Therapeutics' Change in Accured Expenses (Quarter) stood at $1.8 million in 2021, then tumbled by 101.99% to -$35000.0 in 2022, then soared by 15388.57% to $5.4 million in 2023, then plummeted by 57.41% to $2.3 million in 2024, then tumbled by 58.53% to $945000.0 in 2025.
  • Its Change in Accured Expenses was $945000.0 in Q3 2025, compared to $14.0 million in Q2 2025 and -$7.6 million in Q1 2025.